{"entity": "publication", "iuid": "8d8ce4237a5a4c84a238c86dd4afb65b", "timestamp": "2026-08-23T22:12:38.154Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8d8ce4237a5a4c84a238c86dd4afb65b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8d8ce4237a5a4c84a238c86dd4afb65b"}}, "title": "Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.", "authors": [{"family": "Aaseb\u00f8", "given": "Kristine \u00d8", "initials": "K\u00d8", "orcid": "0000-0003-3575-5588", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c33b6dea17eb4502aae023058a58e48a.json"}}, {"family": "Dragomir", "given": "Anca", "initials": "A"}, {"family": "Sundstr\u00f6m", "given": "Magnus", "initials": "M"}, {"family": "Mezheyeuski", "given": "Artur", "initials": "A"}, {"family": "Edqvist", "given": "Per-Henrik", "initials": "PH"}, {"family": "Eide", "given": "Geir Egil", "initials": "GE"}, {"family": "Ponten", "given": "Fredrik", "initials": "F"}, {"family": "Pfeiffer", "given": "Per", "initials": "P"}, {"family": "Glimelius", "given": "Bengt", "initials": "B"}, {"family": "Sorbye", "given": "Halfdan", "initials": "H"}], "type": "journal article", "published": "2019-07-00", "journal": {"title": "Cancer Med", "issn": "2045-7634", "volume": "8", "issue": "7", "pages": "3623-3635", "issn-l": "2045-7634"}, "abstract": "Immunotherapy for patients with microsatellite-instable (MSI-H) tumors or BRAF-inhibitors combination treatment for BRAF-mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected population-based studies of these molecular changes are warranted.\n\nA population-based cohort of 798 mCRC patients in Scandinavia was studied. Patient and molecular tumor characteristics, overall survival (OS) and progression-free survival (PFS) were estimated.\n\nHere, 40/583 (7%) tumor samples were MSI-H and 120/591 (20%) were mutBRAF; 87% of MSI-H tumors were mutBRAF (non-Lynch). Elderly (>75 years) had more often MSI-H (10% vs 6%) and MSI-H/mutBRAF (9% vs 4%) tumors. Response rate (5% vs 44%), PFS (4 vs 8 months), and OS (9 vs 18 months) after first-line chemotherapy was all significantly lower in patients with MSI-H compared to patients with microsatellite stable tumors. MSI-H and mutBRAF were both independent poor prognostic predictors for OS (P = 0.049, P < 0.001) and PFS (P = 0.045, P = 0.005) after first-line chemotherapy. Patients with MSI-H tumors received less second-line chemotherapy (15% vs 37%, P = 0.005).\n\nIn unselected mCRC patients, MSI-H and mutBRAF cases were more common than previously reported. Patients with MSI-H tumors had worse survival, less benefit from chemotherapy, and they differed considerably from recent third-line immunotherapy trial patients as they were older and most had mutBRAF tumor (non-Lynch).", "doi": "10.1002/cam4.2205", "pmid": "31070306", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6601706"}], "notes": [], "created": "2026-08-21T11:00:41.700Z", "modified": "2026-08-21T11:00:41.746Z"}